The Effects of Oral Contraceptive Steroids, Menopause and Hormone Replacement Therapy on the Cervical Epithelium

The Cervix: Second Edition

Volumn , Issue , 2009, Pages 128-144

  Tay, Sun Kuie ^a,b   Singer, Albert ^c,d  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

Effects of oral contraceptive steroids; Hormone replacement therapy on cervical epithelium; HRT and cervical carcinogenesis; Mucosal immune system; Mucosal immunity and predisposition to infection; Nuclear cytoplasmic ratio; Oral contraceptive pills (OCPs); Sex steroid receptors in target tissues

Indexed keywords

EID: 84891038809     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444312744.ch9     Document Type: Chapter

References (116)

1. Abati A, Jaffurs W, Wilder AM (1998) Squamous atypia in the atrophic cervical vaginal smear: a new look at an old problem. Cancer 84: 218-225.
2. Abma JC, Chandra A, Musher WD et al. (1997) Fertility, family planning and women's health: new data from the 1995 national survey of family growth. Vital Health Statistics 19: 1-114.
3. Adami H-O, Persson I, Hoover R et al. (1989) Risk of cancer in women receiving hormone replacement therapy. International Journal of Cancer 44: 833-839.
4. al Saleh W, Delvenne P, Greimers R et al. (1995) Assessment of Ki-67 antigen immunostaining in squamous intraepithelial lesions in the uterine cervix. Correlation with histological grades of human papillomavirus. American Journal of Clinical Pathology 104: 154-160.
5. Alvarez-Santin C, Sica A, Rodriguez M et al. (1999) Microglandular hyperplasia of the uterine cervix. Cytologic diagnosis in cervical smears. Acta Cytologica 43: 110-113.
6. Arbeit JM, Howley PM, Hanahan D (1996) Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proceedings of the National Academy of Sciences of the USA 93: 2930-2935.
7. Barlow DH, Brockie JA, Rees CMP (1991) Study of general practice consultation and menopausal problems. British Medical Journal 302: 274-276.
8. Beral V, Banks E, Reeves G (2002) Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360: 942-944.
9. Brinton LA, Reeves WC, Brenes MM et al. (1990) Oral contraceptive use and risk of invasive cervical cancer. International Journal of Epidemiology 19: 4-11.
10. Bulten J, de Wilde PC, Schijf C et al. (2000a) Decreased expression of Ki-67 in atrophic cervical epithelium of post-menopausal women. Journal of Pathology 190: 545-553.
11. Bulten J, de Wilde PC, Boonstra H et al. (2000b) Proliferation in 'atypical' atrophic pap smears. Gynecology and Oncology 79: 225-229.
12. Cano A, Serra V, Rivera J et al. (1990) Expression of estrogen receptors, progesterone receptors, and an estrogen receptor-associated protein in the human cervix during the menstrual cycle and menopause. Fertility and Sterility 54: 1058-1064.
13. Carr BR, Ory H (1997) Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Contraception 55: 267-272.
14. Castellsague X, Muñoz N (2003) Causal relation between cofactors and cervical cancer, global evaluation: review. Journal of the National Cancer Institute Monograph 31: 20-28.
15. Celli G, Darwiche N, De Luca LM (1996) Estrogen induces retinoid receptor expression in mouse cervical epithelia. Experiments in Cell Research 226: 273-282.
16. Ciocca DR, Puy LA, Lo Castro G (1986) Localization of an estrogenresponsive protein in the human cervix during menstrual cycle, pregnancy, and menopause and in abnormal cervical epithelia without atypia. American Journal of Obstetrics and Gynecology 155: 1090-1096.
17. Chan WK, Klock G, Bernard HV (1989) Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. Journal of Virology 63: 3261-3269.
18. Chasen-Taber L, Stampfer MJ (1998) Epidemiology of oral contraceptives and cardiovascular disease. Annals of Internal Medicine 128: 476-477.
19. Chumas JC, Nelson B, Mann WJ et al. (1985) Microglandular hyperplasia of the uterine cervix. Obstetrics and Gynecology 66:406-409.
20. Clarke EA, Hatcher J, McKeown-Eyssen GE et al. (1985) Cervical dysplasia: association with sexual behavior, smoking, and oral contraceptive use? American Journal of Obstetrics and Gynecology 151: 612-616.
21. Coker AL, McCann MF, Hulka BS et al. (1992) Oral contraceptive use and cervical intraepithelial neoplasia. Journal of Clinical Epidemiology 45: 1111-1118.
22. Coker AL, Sanders LC, Bond SM et al. (2001) Hormonal and barrier methods of contraception, oncogenic human papillomaviruses, and cervical squamous intraepithelial lesion development. Journal of Women's Health and Gender Based Medicine 10: 441-449.
23. Critchlow CW, Wolner-Hanssen P, Eschenbach DA et al. (1995) Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific cervical infection, smoking, and douching. American Journal of Obstetrics and Gynecology 173: 534-543.
24. Cunha GR, Shannon JM, Vanderslice KD et al. (1982) Autoradiographic analysis of nuclear estrogen binding sites during postnatal development of the genital tract of female mice. Journal of Steroid Biochemistry 17: 281-286.
25. Dallenbach-Hellweg G (1985) On the origin and histological structure of adenocarcinoma of the endocervix in women under 50 years of age. Pathology in Research and Practice 179: 38-50.
26. Dallenbach-Hellweg G, Fenzel J (1985) Dependence of morphologic changes in portio, cervix and endometrium on dosage or potency of synthetic gestagens Geburtshilfe und Frauenheilkunde 45: 238-243.
27. Daly E, Roche M, Barlow D et al. (1992) HRT: an analysis of benefits, risks and costs. British Medical Bulletin 48: 368-400.
28. de Vet HC, Knipschild PG, Sturmans F (1993) The role of sexual factors in the aetiology of cervical dysplasia. International Journal of Epidemiology 22: 798-803.
29. Duensing S, Lee LY, Duensing A et al. (2000) The human papillomavirus type 16, E6 and E7 oncoproteins co-operate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proceedings of the National Academy of Sciences of the USA 97: 10002-10007.
30. Elson DA, Riley RR, Lacey A et al. (2000) Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Research 60: 1267-1275.
31. Ferenczy A, Gelfand MM, Franco E et al. (1997) Human papillomavirus infection in postmenopausal women with and without hormone therapy. Obstetrics and Gynecology 90: 7-11.
32. Franklin RD, Kutteh WH (1999) Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. Journal of Reproductive Immunology 42: 93-106.
33. Galloway DA, McDougall JK (1996). The disruption of cell-cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Cancer Biology 7: 309-15.
34. Gaton E, Zejdel L, Bernstein D et al. (1982) The effect of estrogen and gestagen on the mucus production of human endocervical cells: a histochemical study. Fertility and Sterility 38: 580-585.
35. Gill EM, Malpica A, Alford RE et al. (2003) Relationship between collagen autofluorescence of the human cervix and menopausal status. Photochemistry and Photobiology 77: 653-658.
36. Gondos B (1976) Histologic changes associated with oral contraceptive usage. Annals of Clinical and Laboratory Science 6: 291-299.
37. Gorodeski GI (2000) Effects of menopause and estrogen on cervical epithelial permeability. Journal of Clinical and Endocrinology and Metabolism 85: 2584-2595.
38. Gould SF, Shannon JM, Cunha GR (1983) The autoradiographic demonstration of estrogen binding in normal human cervix and vagina during the menstrual cycle, pregnancy, and the menopause. American Journal of Anatomy 168: 229-238.
39. Gram IT, Macaluso M, Stalsberg H (1992) Oral contraceptive use and the incidence of cervical intraepithelial neoplasia. American Journal of Obstetrics and Gynecology 167: 40-44.
40. Greeley C, Schroeder S, Silverberg SG (1995) Microglandular hyperplasia of the cervix: a true 'pill' lesion? International Journal of Gynecology and Pathology 14: 50-54.
41. Green J, Berrington de Gonzalez A, Smith JS et al. (2003) Human papillomavirus infection and use of oral contraceptives. British Journal of Cancer 88: 1713-1720.
42. Hague S, MacKenzie IZ, Bicknell R et al. (2002) In-vivo angiogenesis and progestogens. Human Reproduction 17: 786-793.
43. Hatcher RA, Trussel J, Stewart F et al. (1998) Contraceptive Technology, 17th rev. edn. New York: Ardent Media.
44. Hildesheim A, Reeves WC, Brinton LA et al. (1990) Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers. International Journal of Cancer 45: 860-864.
45. Honore LH, Koch M, Brown LB (1991) Comparison of oral contraceptive use in women with adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecological and Obstetric Investigation 32: 98-101.
46. Hubbert NL, Sedman SA, Schiller JT (1992) Human papillomavirus type 16, E6 increases the degradation rate of p53 in human keratinocytes. Journal of Virology 66: 6237-6241.
47. Hull ME, Moghissi KS (1986) Effects of norgestimate (0.250 mg) in combination with ethinyl estradiol (0.035 mg) on cervical mucus. Advances in Contraception 2: 71-77.
48. Hunt K, Vessey M, McPherson K et al. (1987) Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. British Journal of Obstetrics and Gynaecology 94: 620-635.
49. IARC (2006) Monograph on the Evaluation of Carcinogenic Risk to Humans. Vol. 91. Combined oestrogen-progestogen contraceptives and combined oestrogen-progestogen menopausal therapy. Lyon: International Agency for Research on Cancer (in press).
50. Jacobson DL, Peralta L, Farmer M et al. (2000a) Relationship of hormonal contraception and cervical ectopy as measured by computerized planimetry to chlamydial infection in adolescents. Sexually Transmitted Diseases 27: 313-319.
51. Jacobson DL, Peralta L, Graham NM et al. (2000b) Histologic development of cervical ectopy: relationship to reproductive hormones. Sexually Transmitted Diseases 27: 252-258.
52. Jones MW, Silverberg SG (1989) Cervical adenocarcinoma in young women: possible relationship to microglandular hyperplasia and use of oral contraceptives. Obstetrics and Gynecology 73: 984-989.
53. Jovanovic AS, McLachlin CM, Shen L et al. (1995) Postmenopausal squamous atypia: a spectrum including 'pseudo-koilocytosis'. Modern Pathology 8: 408-412.
54. Katira V, Dayal SS (1987) Vaginal cytology in women using oral contraceptives. Journal of the Anatomical Society of India 36: 94-100.
55. Kedzia W, Gozdzicka-Jozefiak A, Kwasniewska A et al. (2000) Relationship between HPV infection of the cervix and blood serum levels of steroid hormones among pre-and postmenopausal women. European Journal of Gynaecological Oncology 21: 177-179.
56. Kessis TD, Slebos RJ, Nelson WG et al. (1993) Human papillomavirus 16, E6 expression disrupts the p53-mediated cellular response to DNA damage. Proceedings of the National Academy of Sciences of the USA 90: 3988-3992.
57. Kirknp W, Singer A (1980) Colposcopy in the management of women with abnormal smears. British Journal of Obstetrics and Gynaecology 87: 322-325.
58. Kuhl H (1996) Comparative pharmacology of newer progestogens. Drugs; 51: 188-215.
59. Kutza J, Smith E, Levy B et al. (2000) Use of hormone replacement therapy (Hrt) and detection of human papillomavirus (HPV) DNA in postmenopausal women. Annals of Epidemiology 10: 465-466.
60. Kwikkel HJ, Boon ME, van Rijswijk MM et al. (1986) Masking effect of hormonal contraceptives on discriminating quantitative features of visually normal intermediate cells in positive and negative cervical smears. Analysis and Quantification of Cytology and Histology 8: 227-232.
61. Lin TT (1984) Progesterone receptor in the human uterine cervix. Acta Medica Okayama 38: 41-48.
62. Liu W, Koebel L, Shipp J et al. (1967) Cytologic changes following the use of oral contraceptives. Obstetrics and Gynecology 30: 228-232.
63. Makabe S, Motta PM, Naguro T et al. (1998) Microanatomy of the female reproductive organs in postmenopause by scanning electron microscopy. Climacteric 1: 63-71.
64. Megevand E, Denny LA, Soeters R et al. (1996) The influence of hormonal status on excision margins after large loop excision of the transformation zone (LLETZ). European Journal of Gynaecological Oncology 17: 223-227.
65. Meisels A, Begin R, Schneider V (1977) Dysplasias of uterine cervix: epidemiological aspects: role of age at first coitus and use of oral contraceptives. Cancer 40: 3076-3081.
66. Mohsenian M, Moghissi KS, Borin K (1981) Effects of norgestimate in combination with ethinyl estradiol on cervical mucus. Contraception 24: 173-181.
67. Molina R, Thomas DB, Dabancens A et al. (1988) Oral contraceptives and cervical carcinoma in situ in Chile. Cancer Research 48: 1011-1015.
68. Moltz L, Becker K (1977) Cribriform polypoid adenomatous (atypical) hyperplasia of the endocervical glands of the uterus under hormonal contraception. European Journal of Obstetric Gynecology and Reproductive Biology 7: 331-336.
69. Monsonego J, Magdelena H, Catalan F et al. (1991) Estrogen and progesterone receptors in cervical human papillomavirus related lesions. International Journal of Cancer 48: 533-539.
70. Montes MB, Ferreira AC, Fenolio JC et al. (2000) Effects of oral contraceptives in vaginal cytology. Pathologica 92: 185-188.
71. Moodley M, Moodley J, Chetty R et al. (2003) The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. International Journal of Gynecology and Cancer 13: 103-110.
72. Moreno V, Bosch FX, Muñoz N et al. (2002) International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359: 1085-1092.
73. New Zealand Contraception and Health Study Group (1994) Risk of cervical dysplasia in users of oral contraceptives, intrauterine devices or depot-medroxyprogesterone acetate. Contraception 50: 431-441.
74. Parazzini F, La Vecchia C, Negri E et al. (1997) Case-control study of oestrogen replacement therapy and risk of cervical cancer. British Medical Journal 315: 85-88.
75. Pater MM, Hughes GA, Hyslop DE et al. (1988) Glucocorticoiddependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. Nature 335: 832-835.
76. Pater A, Bayatpour M, Pater MM (1990) Oncogenic transformation by human papillomavirus type 16 deoxyribonucleic acid in the presence of progesterone or progestins from oral contraceptives. American Journal of Obstetrics and Gynecology 162: 1099-1103.
77. Paterson ME, Allen J, Jordan JA (1982) Effects of the climacteric and sequential mestranol and norethisterone on the cervix and genital tract. British Journal of Obstetrics and Gynaecology 89: 657-664.
78. Persson E, Einhorn N, Pettersson F (1987) A case-control study of oral contraceptive use in women with adenocarcinoma of the uterine cervix. European Journal of Obstetric Gynecology and Reproductive Biology 26: 85-90.
79. Ramos JG, Varayoud J, Bosquiazzo VL et al. (2002) Cellular turnover in the rat uterine cervix and its relationship to estrogen and progesterone receptor dynamics. Biology of Reproduction 67: 735-742.
80. Remoue F, Jacobs N, Miot V et al. (2003) High intraepithelial expression of estrogen and progesterone receptors in the transformation zone of the uterine cervix. American Journal of Obstetrics and Gynecology 189: 1660-1665.
81. Roumen F J, Boon M E, van Velzen D et al. (1996) The cervico-vaginal epithelium during 20 cycles' use of a combined contraceptive vaginal ring. Human Reproduction 11: 2443-2448.
82. Sawaya GF, Grady D, Kerlikowske K et al. (2000) The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS). Annals of Internal Medicine 133: 942-950.
83. Scharl A, Vierbuchen M, Graupner J et al. (1988) Immunohistochemical study of distribution of estrogen receptors in corpus and cervix uteri. Archives of Gynecology and Obstetrics 241: 221-233.
84. Sherr CJ (2000) The Pezcoller lecture: cancer cell cycles revisited. Cancer Research 60: 3689-3695.
85. Singer A (1975) The uterine cervix from adolescence to the menopause. British Journal of Obstetrics and Gynaecology 82: 81-99.
86. Smith EM, Johnson SR, Figuerres EJ et al. (1997) The frequency of human papillomavirus detection in postmenopausal women on hormone replacement therapy. Gynecology and Oncology 65: 441-446.
87. Smith JS, Green J, Berrington de Gonzalez A et al. (2003) Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361: 1915.
88. Stamm WE, Holmes KK (1997) Chlamydia trachomatis of the adult. In: Holmes KK (ed.) Sexually Transmitted Diseases. New York: McGraw Hill.
89. Strahle U, Klock G, Schutz G (1987) A DNA sequence of 15 base pairs is sufficient to mediate both glucocorticoid and progesterone induction of gene expression. Proceedings of the National Academy of Sciences of the USA 84: 7871-7875.
90. Suissa S, Blais L, Spitzer WO et al. (1997) First time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 56: 141-146.
91. Tay SK, Jenkins D, Maddox P et al. (1987a) Subpopulations of Langerhans cells in cervical neoplasia. British Journal of Obstetrics and Gynaecology 94: 10-15.
92. Tay SK, Jenkins D, Maddox P et al. (1987b) Lymphocyte phenotypes in cervical intraepithelial neoplasia and human papillomavirus infection. British Journal of Obstetrics and Gynaecology 94: 16-21.
93. Tay SK, Jenkins D, Maddox P et al. (1987c) Tissue macrophage response in human papillomavirus infection and cervical intraepithelial neoplasia. British Journal of Obstetrics and Gynaecology 94: 1094-1097.
94. Thomas DB, Ray RM (1996) Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. American Journal of Epidemiology 144: 281-289.
95. Toplis PJ, Casemore V, Hallam N et al. (1986) Evaluation of colposcopy in the postmenopausal woman. British Journal of Obstetrics 93: 843-851.
96. Ursin G, Peters RK, Henderson BE et al. (1994) Oral contraceptive use and adenocarcinoma of cervix. Lancet 344: 1390-1394.
97. Valente PT, Hanjani P (1986) Endocervical neoplasia in long-term users of oral contraceptives: clinical and pathologic observations. Obstetrics and Gynecology 67: 695-704.
98. Valente PT, Schantz HD, Schultz M (1994) Microglandular hyperplasia of the uterine cervix. Cytologic diagnosis in cervical smears. Cytologic atypia associated with microglandular hyperplasia. Diagnostic Cytopathology 10: 326-331.
99. Vessey MP, Lawless M, McPherson K et al. (1983) Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill. Lancet 2: 930-934.
100. Von Knebel Doeberitz M, Bankrecht T, Bartsch D et al. (1991) Influence of chromosomal integration on glucocorticoid-regulated transcription of growth stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proceedings of the National Academy of Sciences of the USA 88: 1411-1415.
101. Wang H, Stjernholm Y, Ekman G et al. (2001) Different regulation of oestrogen receptors alpha and beta in the human cervix at term pregnancy. Molecular Human Reproduction 7: 293-300.
102. White HD, Yeaman GR, Givan AL et al. (1997) Mucosal immunity in the human female reproductive tract: cytotoxic T lymphocyte function in the cervix and vagina of premenopausal and postmenopausal women. American Journal of Reproductive Immunology 37: 30-38.
103. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995) Venous thromboembolic disease and combined oral contraceptives: results of an international, multicentre, case-controlled study. Lancet 346: 1575-1582.
104. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1997) Acute myocardial infarction and combined oral contraceptives: results of an international, multicentre, case-controlled study. Lancet 349: 1202-1209.
105. Wilkes HC, Meades TW (1991) Hormone replacement therapy in general practice; a survey of doctors in the MRC's general practice framework. British Medical Journal 302: 1317-1320.
106. Williams DB, Moley KH (1994) Progestin replacement in the menopause: effects on the endometrium and serum lipids. Current Opinion in Obstetrics and Gynecology 6: 284-292.
107. Wira CR, Rossoth RM, Kavshic C (2003) Antigen-presenting cells in the female reproductive tract: influence of estradiol on antigen presentation of vaginal cells. Epidemiology 141: 2877-2885.
108. Wren BG (1985) Estrogen replacement therapy in the management of an endocrine deficiency disease. Medical Journal of Australia 142 (Suppl.): S1-S5.
109. Wright TC, Holinka CF, Ferenczy A (2002) Estriol-induced hyperplasia in endometrial biopsies from women on hormone replacement therapy. American Journal of Surgical Pathology 10: 1269-1275.
110. Yahr LJ, Lee KR (1991) Cytologic findings in microglandular hyperplasia of the cervix. Diagnostic Cytopathology 7: 248-251.
111. Yasui T, Uemura H, Tezuka M et al. (2001) Biological effects of hormone replacement therapy in relation to serum estradiol levels. Hormone Research 56: 38-44.
112. Ylitalo N, Sorensen P, Josefsson A et al. (1999) Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. International Journal of Cancer 81: 357-365.
113. Young RH, Scully RE (1992) Uterine carcinomas simulating microglandular hyperplasia. A report of six cases. American Journal of Surgical Pathology 16: 1092-1097.
114. Yuan F, Auborn K, James C (1999) Altered growth and viral gene expression in HPV-16 containing cancer lines treated with progesterone. Cancer Investigations 17: 19-29.
115. Zimmermann H, Degenkolbe R, Bernard HU et al. (1999) The human papillomavirus type 16, E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional co-activator CBP/p300. Journal of Virology 73: 6209-6219.
116. Zondervan KT, Carpenter LM, Painter R et al. (1996) Oral contraceptives and cervical cancerafurther findings from the Oxford Family Planning Association contraceptive study. British Journal of Cancer 73: 1291-1297.